MIM
IRD

MetLife Investment Management’s Opus Genetics IRD Stock Holding History

MetLife Investment Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$132K Buy
+32,208
New +$150K ﹤0.01% 2643

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MetLife Investment Management's IRD Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Opus Genetics (IRD) in Q2 2026: 32,208 shares worth $132K. The stake represents ﹤0.01% of the portfolio and ranks #2643 among its holdings.

103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • MetLife Investment Management held 32,208 shares of Opus Genetics worth $132K as of Q2 2026.
  • Opus Genetics was a new MetLife Investment Management position in Q2 2026.
  • Opus Genetics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2643 holding.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.